A5033515076- Esophageal Cancer Research and Treatment
- Eosinophilic Esophagitis
- Esophageal and GI Pathology
- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- Gastric Cancer Management and Outcomes
- Cancer-related gene regulation
- Eosinophilic Disorders and Syndromes
- Genetic factors in colorectal cancer
- Wnt/β-catenin signaling in development and cancer
- IL-33, ST2, and ILC Pathways
- Epigenetics and DNA Methylation
- Cytokine Signaling Pathways and Interactions
- Cancer Cells and Metastasis
- Inflammatory mediators and NSAID effects
- RNA modifications and cancer
- Digestive system and related health
- Inflammatory Bowel Disease
- Dysphagia Assessment and Management
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Tracheal and airway disorders
- Cardiovascular Disease and Adiposity
- Gastrointestinal Tumor Research and Treatment
- NF-κB Signaling Pathways
Baylor University Medical Center
2012-2025
Baylor Medical Center at Garland
2017-2025
Baylor Scott & White Health
2021-2025
The University of Texas at Arlington
2024
Texas A&M Health Science Center
2024
Veterans Health Administration
2004-2023
VA North Texas Health Care System
2009-2019
RELX Group (Netherlands)
2018
The University of Texas Health Science Center at Houston
2018
Rhode Island Hospital
2018
Barrett's esophagus, a condition of intestinal metaplasia the is associated with an increased risk esophageal adenocarcinoma. We assessed whether endoscopic radiofrequency ablation could eradicate dysplastic esophagus and decrease rate neoplastic progression.
By expressing two genes (hTERT and Cdk4), we have developed a method to reproducibly generate continuously replicating human bronchial epithelial cell (HBEC) lines that provide novel resource study the molecular pathogenesis of lung cancer differentiation cells. Twelve biopsy specimens obtained from persons with without were placed into short-term culture serially transfected retroviral constructs containing cyclin-dependent kinase (Cdk) 4 telomerase reverse transcriptase (hTERT), resulting...
<h3>Objective</h3> Eosinophilic oesophagitis (EoE) and gastro-oesophageal reflux disease (GORD) can have similar clinical histological features. Proton pump inhibitors (PPIs) are used to distinguish the disorders, with assumption that only GORD respond PPIs. Oesophageal expression of eotaxin-3 stimulated by Th2 cytokines might contribute oesophageal eosinophilia in EoE. cytokine effects on oesophagus not known. The objective authors was explore molecular mechanisms squamous cells from...
Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE the only known precursor to esophageal adenocarcinoma, highly lethal cancer an increasing incidence over last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology propose recommendations for definition diagnosis BE, screening surveillance patients medical endoscopic treatment its early neoplasia. Important changes...
Background Patients who have esophageal eosinophilia without gastroesophageal reflux disease (GERD) nevertheless can respond to proton pump inhibitors (PPIs), which anti-inflammatory actions independent of effects on gastric acid secretion. In cell cultures, omeprazole has been reported inhibit Th2 cytokine-stimulated expression eotaxin-3, an eosinophil chemoattractant contributing in eosinophilic esophagitis (EoE). The objective this study was elucidate molecular mechanisms underlying PPI...
The histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been studied prospectively in humans. Recent studies animals challenged the traditional notion that esophagitis develops when esophageal surface epithelial cells are exposed to lethal chemical injury from refluxed acid.To evaluate features of inflammation GERD study its pathogenesis.Patients Dallas Veterans Affairs Medical Center who had successfully treated proton pump inhibitors (PPIs) began...
Heartburn that persists despite proton-pump inhibitor (PPI) treatment is a frequent clinical problem with multiple potential causes. Treatments for PPI-refractory heartburn are of unproven efficacy and focus on controlling gastroesophageal reflux reflux-reducing medication (e.g., baclofen) or antireflux surgery dampening visceral hypersensitivity neuromodulators desipramine).
Barrett's esophagus develops when refluxed gastric juice injures the esophageal squamous lining and injury heals through a metaplastic process in which intestinal-type columnar cells replace ones. The progenitor cell that gives rise to metaplasia is not known, nor it known why condition predisposed malignancy. We studied contribution of bone marrow stem development an animal model. Twenty female rats were given lethal dose irradiation followed by tail vein injection from male rats. Ten days...
Barrett esophagus (BE) is defined by the presence of metaplastic esophageal columnar epithelium with goblet cells within endoscopically recognizable areas esophagus. However, some carcinomas in BE, or from gastroesophageal junction region, develop mucosa devoid cells. biologic properties, pathogenesis, and risk malignancy metaplastic, nongoblet epithelium, is, essentially, unknown. In this study, 89 patients were evaluated immunohistochemically for markers intestinal differentiation, such as...